Biogen bags FDA nod for high dose SPINRAZA in spinal muscular atrophy
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Subscribe To Our Newsletter & Stay Updated